Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 294.00
Bid: 292.00
Ask: 298.00
Change: -3.00 (-1.01%)
Spread: 6.00 (2.055%)
Open: 294.00
High: 294.00
Low: 294.00
Prev. Close: 298.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

14 Jul 2010 09:18

RNS Number : 3215P
Hutchison China Meditech Limited
14 July 2010
 



For filings with the FSA include the annex

For filings with issuer exclude the annex

 

TR-1: notification of major interests in shares i

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

HUTCHISON CHINA MEDITECH LTD

 

2. Reason for the notification (please tick the appropriate box or boxes) :

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii

 

Slater Investments Ltd

 

4. Full name of shareholder(s)  (if different from

3.): iv

5. Date of the transaction and date on which the threshold is crossed or reached: v

 

12 July 2010

6. Date on which issuer notified:

 

13 July 2010

7. Threshold(s) that is/are crossed or reached: vi, vii

 

Over 7%

 

1.

1. 1. 1.

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

 

if possible using the ISIN CODE

Situation previous to the triggering transaction

 

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

B11Y2X4

3,228,165

3,228,165

2,126,769

2,126,769

1,619,000

3.11%

4.11%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion Period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

3,745,769

7.24%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

13. Additional information:

14. Contact name:

 

Nicola Smith

15. Contact telephone number:

 

+44 20 7330 6130

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUSAWRRNABARR
Date   Source Headline
16th Jun 20237:00 amRNSPhase III FRESCO-2 Results in The Lancet
15th Jun 20233:39 pmRNSMAA of Fruquintinib Validated by the EMA
9th Jun 202310:30 amRNSHUTCHMED Highlights Presentations at EHA and ICML
6th Jun 202310:00 amRNSLTIP and Share Option Scheme
31st May 20239:30 amRNSTotal Voting Rights
26th May 20237:00 amRNSFruquintinib NDA Granted Priority Review by FDA
26th May 20237:00 amRNSHUTCHMED Highlights Presentations at ASCO 2023
17th May 20239:30 amRNSStandard form for notification of major holdings
12th May 20231:15 pmRNSAnnual General Meeting Poll Results
12th May 20239:30 amRNSBoard of Directors and Board Committee Membership
10th May 20239:30 amRNSAppointment of Independent NED
28th Apr 20239:30 amRNSTotal Voting Rights
21st Apr 20239:30 amRNSVesting of awards under the LTIP
18th Apr 20237:00 amRNSNDA Acceptance in China for Fruquintinib
12th Apr 20237:00 amRNSPresentations at AACR Annual Meeting 2023
11th Apr 20239:30 amRNSIntended Retirement of Independent NED
11th Apr 20239:30 amRNS2022 Annual Report and Notice of AGM
4th Apr 202310:30 amRNSHUTCHMED Initiates Registration Phase Enrollments
31st Mar 20239:30 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSRolling Submission of Fruquintinib US NDA Complete
14th Mar 20231:30 pmRNSClosing of Fruquintinib License to Takeda
8th Mar 20238:30 amRNSDirector's Share Dealing
6th Mar 20238:30 amRNSVesting of awards under the LTIP
28th Feb 202312:15 pmRNSPublication of Form 20-F
28th Feb 20238:30 amRNS2022 Full Year Results and Business Updates
27th Feb 202310:00 amRNSEnrollment Completed in Phase 2 Amdizalisib trial
31st Jan 20238:30 amRNSNotice of Results
23rd Jan 20238:00 amRNSLicense to Takeda for Fruquintinib outside China
18th Jan 20232:30 pmRNSInclusion of ORPATHYS in NRDL in China
3rd Jan 20238:30 amRNSEnrollment Completed in Phase 3 Trial
30th Dec 20228:30 amRNSBlocklisting Six Monthly Return
19th Dec 202210:00 amRNSFDA NDA Rolling Submission for Fruquintinib
15th Nov 20227:00 amRNSHUTCHMED Announces Strategy Update
14th Nov 20227:00 amRNSPositive Topline Phase 3 Result in Fruquintinib
27th Oct 202212:30 pmRNSHUTCHMED Initiates Phase 2/3 Trial of Fruquintinib
21st Oct 20229:30 amRNSVesting of awards under the LTIP
10th Oct 20229:30 amRNSPhase II/III Trial of Sovleplenib for in China
30th Sep 20229:30 amRNSTotal Voting Rights
14th Sep 202211:00 amRNSShare Option Scheme and Long Term Incentive Plan
8th Sep 20227:00 amRNSFRESCO-2 Colorectal Cancer MRCT Data Highlights
23rd Aug 202210:00 amRNSHolding(s) in Company
23rd Aug 20229:30 amRNSHUTCHMED To Present FRESCO-2 Data at ESMO 2022
9th Aug 20229:30 amRNSFirst Participant in Phase I Trial of IMG-004
8th Aug 20229:30 amRNSPreliminary results from SAVANNAH Phase 2 Trial
8th Aug 20227:00 amRNSFRESCO-2 Study Has Met Primary Endpoint
1st Aug 202212:04 pmRNSInterim Results and Business Updates
1st Aug 20227:00 amRNSHUTCHMED Initiates Bridging Study of Tazemetostat
15th Jul 20229:30 amRNSHUTCHMED Initiates Phase I Trial of HMPL-A83
13th Jul 20227:00 amRNSResults of SAVANNAH Global Phase II Trial at WCLC
6th Jul 20227:00 amRNSFirst Participants in Phase I Trial of IMG-007

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.